<DOC>
	<DOCNO>NCT00392951</DOCNO>
	<brief_summary>Treatment patient autoimmune destruction blood cell poor . The part body fight infection call immune system white blood cell ( WBCs ) part immune system . Normally , person 's body create WBCs fight infection eliminate WBCs stop help body function . Patients autoimmune destruction blood cell difficulty eliminate old WBCs . The abnormal WBCs build damage healthy cell , lead anemia , fatigue , jaundice , internal bleeding , infection , cancer . Few effective medication exist treatment patient autoimmune cytopenia commonly use fraught side effect . Nevertheless , scientific understand autoimmune disease improve , direct less toxic therapy become available . A number group study efficacy medication call sirolimus patient autoimmune disease . This medicine FDA-approved 20 year . Sirolimus medicine use child disease . Sirolimus work , part , eliminate old abnormal WBCs . Our group others show sirolimus effective mouse autoimmunity child rare condition call Autoimmune Lymphoproliferative Syndrome ( ALPS ) . We believe sirolimus help child autoimmune cytopenia . We believe improve symptom make less sick . We propose study sirolimus child chronic and/or refractory autoimmune cytopenia .</brief_summary>
	<brief_title>Sirolimus Autoimmune Disease Blood Cells</brief_title>
	<detailed_description>Patients autoimmune destruction hematopoietic cell frequently severe debilitate disease require aggressive frequent medical management . These patient often treat non-specific immunosuppressive medication limit efficacy untoward side-effect profile . We investigate use immunosuppressive anti-cancer agent , sirolimus patient autoimmune cytopenias syndrome : Autoimmune Lymphoproliferative Syndrome ( ALPS ) . ALPS primary immune deficiency cause mutation Fas apoptotic pathway , lead abnormal lymphocyte survival . Clinical manifestation patient ALPS typically include autoimmune cytopenia , lymphadenopathy , hepatosplenomegaly , propensity develop secondary malignancy . Thus , far find excellent result albeit total number patient treat small . Sirolimus signal transduction inhibitor tolerable side effect profile . Sirolimus two property make attractive agent treat patient autoimmune cytopenias syndrome , include ALPS . First , sirolimus induces apoptosis normal abnormal white blood cell , cell type dysregulated patient autoimmune disease . In addition , sirolimus increase T cell subset call Regulatory T cell ( Tregs ) . Tregs cell population design suppress immune system control autoimmunity . These combined property make sirolimus unique compare immunosuppressive agent . Ample preclinical clinical data exists demonstrate sirolimus effective patient autoimmunity . Accordingly , hypothesize sirolimus safe efficacious medication patient autoimmune destruction blood cells.. We plan confirm hypothesis perform pilot series child autoimmune cytopenia either refractory standard therapy significant toxicity standard treatment . Our primary aim define toxicity administration oral sirolimus child autoimmune cytopenia . Our secondary aim evaluate efficacy sirolimus child autoimmune cytopenia , determine trough level sirolimus use patient , evaluate effect sirolimus intracellular target mammalian target rapamycin ( mTOR ) . We intend enroll 50 child autoimmune cytopenias treat 6 month period , however , find sirolimus effective , anticipate child continue take sirolimus long period time . We anticipate result work establish sirolimus effective well tolerate medication lead directly large national phase II clinical trial .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age &gt; 12 month &lt; 30 year time study entry Diagnosis autoimmune cytopenia require treatment medication At least one following : Autoimmune Neutropenia , Autoimmune Hemolytic Anemia , and/or Autoimmune Thrombocytopenia Must proven autoimmune either document autoantibody ( positive direct anti globulin test , positive antineutrophil , and/or antiplatelet antibody ) and/or document clinical response immunosuppression Autoimmune Cytopenias idiopathic ( Idiopathic Thrombocytopenic Purpura ( ITP ) , Autoimmune Hemolytic Anemia ( AIHA ) , Autoimmune Neutropenia ( AIN ) , Evans syndrome ) secondary one follow condition : Lupus , Rheumatoid Arthritis ( RA ) , ALPS ( Autoimmune Lymphoproliferative Syndrome ) , Inflammatory bowel disease ( IBD ) Patients must chronic disease diagnose either document cytopenia syndrome ( Lupus , ALPS , RA , IBD ) , Evans syndrome define idiopathic destruction multiple blood cell type , and/or disease &gt; 6 month Patients must refractory unable tolerate standard frontline therapy autoimmune cytopenia ( corticosteroid and/or IVIG ) Patients may take secondline agent autoimmune cytopenia ( mycophenolate mofetil , cyclosporine , tacrolimus , mercaptopurine , and/or methotrexate ) time study entry ; however , attempt make wean agent . Patients may stay combination sirolimus calcineurin inhibitor great 4 week Informed consent/assent MUST obtain prior initiating treatment Patient must able consume oral medication form tablet solution Pregnancy breast feeding Uncontrolled infection Known allergy Sirolimus components Patients documented malignancy therapy remission Patients meet organ function requirement list protocol Patients document history severe combine immunodeficiency human immunodeficiency virus infection ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALPS</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Cytopenias</keyword>
	<keyword>Treatment</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Lymph Nodes</keyword>
	<keyword>Spleen</keyword>
	<keyword>Hemolytic Anemia</keyword>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>ITP</keyword>
	<keyword>Lupus</keyword>
</DOC>